INmune Bio
INMB
74 hedge funds and large institutions have $7.93M invested in INmune Bio in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 10 closing their positions.
50% more call options, than puts
Call options by funds: $154K | Put options by funds: $103K
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
1.61% more ownership
Funds ownership: 17.51% → 19.12% (+1.6%)
1% more funds holding
Funds holding: 73 → 74 (+1)
18% less capital invested
Capital invested by funds: $9.64M → $7.93M (-$1.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$544K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$168K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$146K |
| 4 |
State Street
Boston,
Massachusetts
|
+$113K |
| 5 |
Morgan Stanley
New York
|
+$83.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$169K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
-$103K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$97.8K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$68.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$49.6K |
INMB Hedge Fund Activity: Q4 2025 in Review
74 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2025, worth a combined $7.93M — down 18% from $9.64M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new INMB positions and 10 closed out — a net gain of 2 holders — while 24 added to existing stakes and 20 trimmed.
The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $544K. The largest seller was UBS Group, cutting an estimated $169K.
- 74 institutional investors held INmune Bio (INMB) as of Q4 2025, up from 73 in Q3 2025.
- Funds reported $7.93M of INmune Bio stock for Q4 2025, down 18% quarter-over-quarter.
- 12 funds opened new INmune Bio positions in Q4 2025 and 10 closed out, a net change of +2 holders.
- The largest INmune Bio buyer in Q4 2025 was Dauntless Investment Group, an estimated $544K added.
- The largest INmune Bio seller in Q4 2025 was UBS Group, an estimated $169K sold.
Based on aggregated 13F filings for Q4 2025.